Market Cap 1.22B
Revenue (ttm) 277.25M
Net Income (ttm) 27.31M
EPS (ttm) N/A
PE Ratio 50.95
Forward PE N/A
Profit Margin 9.85%
Debt to Equity Ratio 0.08
Volume 1,112,205
Avg Vol 1,669,060
Day's Range N/A - N/A
Shares Out 117.27M
Stochastic %K 97%
Beta 1.13
Analysts Sell
Price Target $22.67

Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccin...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 510 848 5100
Fax: 510 848 1327
Address:
2100 Powell Street, Suite 720, EmeryVille, United States
KWalzz
KWalzz Oct. 27 at 1:38 PM
$DVAX we need: 1. record Heplisav SALES GROWTH 2. positive news on Dialysis fail 3. a MEGA LICENSING deal, for example CpG1018 used by BP 4. if possible remove more tired directors like Janssen
1 · Reply
Buy_dvax100
Buy_dvax100 Oct. 27 at 1:35 PM
$DVAX 👀
0 · Reply
KWalzz
KWalzz Oct. 27 at 10:37 AM
$DVAX update on SI (as always: for whoever cares about this). it is a bit up ... volume's gone down ...
0 · Reply
AAROELA
AAROELA Oct. 27 at 1:49 AM
$DVAX A Fresh Look at Dynavax Technologies (DVAX) Valuation Following Positive Z-1018 Shingles Vaccine Trial Update https://www.webullapp.com/news-detail/13745174714072064?__app_cfg__=%7B%22supportTheme%22%3Atrue%7D&sourcePage=Stock_NewsList&tickerId=913253749&audioNewsPlayedDuration=&theme=1&color=2&hl=en&android_sdk_int=31&canary-version=&_v=1&sp=1&statusBarHeightV2=37&isLite=false&wbFontSetting=medium&wbFontUnit=29&wbFontSize=32&isSubsNews=false
0 · Reply
Barry64
Barry64 Oct. 24 at 9:43 PM
$DVAX Why am I still invested here? Based on data from ClinicalTrials.gov, PubMed, and Dynavax's pipeline disclosures (as of October 2025), there are over 30 distinct clinical trials involving CpG 1018. For scifi fans, what spice was for Dune, CpG 1018 is for Dynavax and future vaccines.
0 · Reply
KWalzz
KWalzz Oct. 23 at 1:16 PM
$DVAX and we need NEWS about Janssens's DIALYSIS FAIL ! IT IS ABOUT TIME, RYAN !!! tik, tok, tik, tok ... time is running out ...
0 · Reply
KWalzz
KWalzz Oct. 23 at 1:14 PM
$DVAX we need real news! and we do not need alum adjuvant lies by maha dummies which may affect at most pediatric vaccines in 5 years from now or so ... Dynavax has no pediatric vaccine, and most likely will never have one. What we need is a MAJOR LICENSING deal so bad. would catapult us to a new level here ...
0 · Reply
AccuRoger
AccuRoger Oct. 22 at 9:19 PM
$DVAX If you are interested in the MAHA CDC perspective on Alum in vaccines, this article provides detail. There is dismissal of any evidence that does not support their thesis. Heplisav is not at risk as alum is not used. The Shingles dose being tested in elderly adults does employ alum along with CpG 1018. https://www.themahareport.com/p/cdc-establishes-new-workgroup-to
0 · Reply
AccuRoger
AccuRoger Oct. 22 at 8:56 PM
$DVAX The EU recognizes Heplisav superiority for patients with HIV. Management should share the insight and discuss their plan for expanding access. Analysts can ask a real question this time. Quote: Vaccination: RSV and a Major Hepatitis B Overhaul The RSV vaccine is now recommended for people aged 75 years or older. The hepatitis B vaccination section is substantially revised. New CpG-adjuvanted vaccines enable near-100% response rates in people living with HIV, including prior nonresponders, Rockstroh said, while noting that reimbursement remains inconsistent across Europe. https://www.eatg.org/hiv-news/eacs-guidelines-2025-hiv-updates-put-comorbidities-first-art-on-cruise-control/
1 · Reply
KWalzz
KWalzz Oct. 21 at 8:14 PM
$DVAX so oooold news ....
0 · Reply
Latest News on DVAX
3 Of My Favorite Biotech Stocks Under $10

Sep 29, 2025, 1:15 PM EDT - 4 weeks ago

3 Of My Favorite Biotech Stocks Under $10

FOLD MRNA NUVB PFE


Dynavax Technologies: A Dip To Accumulate

Aug 11, 2025, 8:41 AM EDT - 2 months ago

Dynavax Technologies: A Dip To Accumulate


Dynavax Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:00 PM EDT - 2 months ago

Dynavax Reports Second Quarter 2025 Financial Results


Dynavax Comments on Glass Lewis Recommendation

Jun 4, 2025, 4:59 PM EDT - 5 months ago

Dynavax Comments on Glass Lewis Recommendation


Deep Track Capital Comments on ISS Recommendation

May 23, 2025, 6:12 PM EDT - 5 months ago

Deep Track Capital Comments on ISS Recommendation


Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking Good

May 21, 2025, 11:48 PM EDT - 5 months ago

Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking Good


Dynavax Files Preliminary Proxy Statement

Apr 3, 2025, 5:40 PM EDT - 7 months ago

Dynavax Files Preliminary Proxy Statement


Dynavax to Participate in Upcoming Investor Conferences

Feb 25, 2025, 4:10 PM EST - 8 months ago

Dynavax to Participate in Upcoming Investor Conferences


Dynavax Advances Board Refreshment Program

Jan 27, 2025, 6:00 AM EST - 9 months ago

Dynavax Advances Board Refreshment Program


KWalzz
KWalzz Oct. 27 at 1:38 PM
$DVAX we need: 1. record Heplisav SALES GROWTH 2. positive news on Dialysis fail 3. a MEGA LICENSING deal, for example CpG1018 used by BP 4. if possible remove more tired directors like Janssen
1 · Reply
Buy_dvax100
Buy_dvax100 Oct. 27 at 1:35 PM
$DVAX 👀
0 · Reply
KWalzz
KWalzz Oct. 27 at 10:37 AM
$DVAX update on SI (as always: for whoever cares about this). it is a bit up ... volume's gone down ...
0 · Reply
AAROELA
AAROELA Oct. 27 at 1:49 AM
$DVAX A Fresh Look at Dynavax Technologies (DVAX) Valuation Following Positive Z-1018 Shingles Vaccine Trial Update https://www.webullapp.com/news-detail/13745174714072064?__app_cfg__=%7B%22supportTheme%22%3Atrue%7D&sourcePage=Stock_NewsList&tickerId=913253749&audioNewsPlayedDuration=&theme=1&color=2&hl=en&android_sdk_int=31&canary-version=&_v=1&sp=1&statusBarHeightV2=37&isLite=false&wbFontSetting=medium&wbFontUnit=29&wbFontSize=32&isSubsNews=false
0 · Reply
Barry64
Barry64 Oct. 24 at 9:43 PM
$DVAX Why am I still invested here? Based on data from ClinicalTrials.gov, PubMed, and Dynavax's pipeline disclosures (as of October 2025), there are over 30 distinct clinical trials involving CpG 1018. For scifi fans, what spice was for Dune, CpG 1018 is for Dynavax and future vaccines.
0 · Reply
KWalzz
KWalzz Oct. 23 at 1:16 PM
$DVAX and we need NEWS about Janssens's DIALYSIS FAIL ! IT IS ABOUT TIME, RYAN !!! tik, tok, tik, tok ... time is running out ...
0 · Reply
KWalzz
KWalzz Oct. 23 at 1:14 PM
$DVAX we need real news! and we do not need alum adjuvant lies by maha dummies which may affect at most pediatric vaccines in 5 years from now or so ... Dynavax has no pediatric vaccine, and most likely will never have one. What we need is a MAJOR LICENSING deal so bad. would catapult us to a new level here ...
0 · Reply
AccuRoger
AccuRoger Oct. 22 at 9:19 PM
$DVAX If you are interested in the MAHA CDC perspective on Alum in vaccines, this article provides detail. There is dismissal of any evidence that does not support their thesis. Heplisav is not at risk as alum is not used. The Shingles dose being tested in elderly adults does employ alum along with CpG 1018. https://www.themahareport.com/p/cdc-establishes-new-workgroup-to
0 · Reply
AccuRoger
AccuRoger Oct. 22 at 8:56 PM
$DVAX The EU recognizes Heplisav superiority for patients with HIV. Management should share the insight and discuss their plan for expanding access. Analysts can ask a real question this time. Quote: Vaccination: RSV and a Major Hepatitis B Overhaul The RSV vaccine is now recommended for people aged 75 years or older. The hepatitis B vaccination section is substantially revised. New CpG-adjuvanted vaccines enable near-100% response rates in people living with HIV, including prior nonresponders, Rockstroh said, while noting that reimbursement remains inconsistent across Europe. https://www.eatg.org/hiv-news/eacs-guidelines-2025-hiv-updates-put-comorbidities-first-art-on-cruise-control/
1 · Reply
KWalzz
KWalzz Oct. 21 at 8:14 PM
$DVAX so oooold news ....
0 · Reply
BigSqueezeComing
BigSqueezeComing Oct. 21 at 8:04 PM
$DVAX Part 1 of the Phase 1/2 study showed immune responses comparable to GSK’s Shingrix and a favorable tolerability profile, and they’ve started Part 2 (head-to-head in ≥70 yrs). Starting the next part quickly is a good signal.
0 · Reply
BigSqueezeComing
BigSqueezeComing Oct. 21 at 8:03 PM
$DVAX Good news
1 · Reply
BigSqueezeComing
BigSqueezeComing Oct. 21 at 8:03 PM
$DVAX Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial By PR Newswire | October 21, 2025, 4:01 PM
0 · Reply
HeadlessHorsemen
HeadlessHorsemen Oct. 21 at 5:02 PM
$DVAX des·ul·to·ry /ˈdesəlˌtôrē,dəˈsəltərē/ adjective adjective: desultory lacking a plan, purpose, or enthusiasm. I think that sums things up re DVAX
0 · Reply
hermitkatt
hermitkatt Oct. 21 at 3:54 PM
$DVAX build a position from here..
0 · Reply
Stokwhisperer
Stokwhisperer Oct. 21 at 2:31 PM
$DVAX So glad I bailed last spring. But happy to see changes are coming internally. Stagnant for too many years now!
0 · Reply
Barry64
Barry64 Oct. 20 at 11:14 AM
$DVAX FYI: Form 8-K: Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In connection with an internal realignment of various management roles and responsibilities, on October 15, 2025, the Board of Directors (the “Board”) of Dynavax Technologies Corporation (the “Company”) approved the transition of David F. Novack from his roles as the Company’s President and Chief Operating Officer to his new roles as Senior Vice President and Chief Operating Officer, effective January 1, 2026. The Board also approved the removal of Robert Janssen, M.D.’s roles as Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs, effective upon the earlier to occur of (a) the date the Company employs a new Chief Medical Officer and (b) March 2, 2026, and further approved the conclusion of Dr. Janssen’s employment as of March 2, 2026.
2 · Reply
HeadlessHorsemen
HeadlessHorsemen Oct. 17 at 5:53 PM
$DVAX From the WSJ yesterday. Glass Lewis, which bailed out Scot Meyers et al, is no longer going to be giving proxy advice for voting. This is great news for us as the lazy institutional investors will now be freed to vote out incompetent management.
1 · Reply
Buy_dvax100
Buy_dvax100 Oct. 17 at 3:53 PM
$DVAX 👍
0 · Reply
KWalzz
KWalzz Oct. 16 at 10:19 AM
$DVAX LOL, "The Board also approved the removal of Robert Janssen" Janssen oversaw clinical strategy, and this included the dialysis trial and the DIALYSIS FAIL. If it is not for his age he got removed for this. First good step here in case later strikes.
0 · Reply
KWalzz
KWalzz Oct. 16 at 10:16 AM
$DVAX new 8-K: https://investors.dynavax.com/node/21871/html
0 · Reply
KWalzz
KWalzz Oct. 16 at 10:14 AM
$DVAX we need a MAJOR LICENSING DEAL here, and if Spencer and Myers are not able to deliver this, THEY HAVE TO GO !! I dare say no one is really bullish here (except the usual paid pumpers) until this all is resolved.
0 · Reply